youtube.com/watch?v=S_JvSVl...
thelancet.com/journals/lano...
Some phase 2 early results : adding LuPSMA to (ADT + docetaxel) has generated a strong result in men with "newly diagnosed high-volume mHSPC"
April 2020 the trial started.
" 25 (41%) of 61 patients (95% CI 30–54) in the [177Lu]Lu-PSMA-617 plus docetaxel group had undetectable PSA at 48 weeks compared with ten (16%) of 61 patients (9–28) in the docetaxel alone group (OR 3·88, 95% CI 1·61–9·38; p=0·0020). "
The patients were selected for the trial if they had high PSA and PSMA expression. A surprising number of patients initially selected were rejected for "discordant" application ( supposedly high volume cancer, but found to have low PSMA expression or low PSA due to initial ADT, or very heterogeneous disease ).
Management of the Metastases in Oligometastatic Prostate Cancer 
Modified Citrus Pectin - reply from Dr Eliaz
